Nobody in the world, with any intelligence, cares to spend hundreds of dollars on a device used solely to help Google spy on them.
Smartphones and Tablets Now Universally Known As Threats to Life, Freedom, Privacy, Social life due to Google’s abuses of the data of every human. Intel says “screw that” and begins exit of the waning market as Apple iPhonres crash and the public turns away from Silicon Valley!
Intel cuts Atom chips, basically giving up on the smartphone and tablet markets
Intel is refocusing on ‘products that deliver higher returns.’
Intel could be on the verge of exiting the market for smartphones and standalone tablets, wasting billions of dollars it spent trying to expand in those markets.
The company is immediately canceling Atom chips, code-named Sofia and Broxton, for mobile devices, an Intel spokeswoman confirmed.
These are the first products on the chopping block as part of Intel’s plan to reshape operations after announcing plans this month to cut 12,000 jobs.
The news of the chip cuts was first reported by analyst Patrick Moorhead in an article on Forbes’ website.
Resources originally dedicated to Broxton and Sofia chips will be moved to “products that deliver higher returns and advance our strategy,” Intel’s spokeswoman said in an email.
Intel’s mobile chip roadmap now has a giant hole after the cancellation of the chips. Intel’s existing smartphone and tablet-only chips are aging and due for upgrades, and no major replacements are in sight. Sofia is already shipping, and Broxton was due to ship this year but had been delayed.
Intel is also phasing out its Atom X5 line of tablet chips code-named Cherry Trail, which is being replaced by Pentium and Celeron chips code-named Apollo Lake, aimed more at hybrids than pure tablets. Many PC makers are already choosing Intel’s Skylake Core M processors over Cherry Trail for hybrids and PC-like tablets.
Intel doesn’t view tablets as a standalone market any longer, with form factors quickly merging. The company will continue to support current tablet customers with existing chips, the Intel spokeswoman said.
“In terms of Cherry Trail, form factor boundaries are increasingly blurring in the mobile computing market, and we no longer look at tablets as a stand-alone segment,” an Intel spokeswoman said in an email Friday afternoon. “Our product roadmap reflects that. We will continue to support our tablet customers with Sofia 3G/3GR, Bay Trail and Cherry Trail now, and later with Apollo Lake and some SKUs from our Core processor family.”
Some products were on tap to get axed after Intel said it would review product lines and projects while restructuring operations. Intel had already deemphasized its bread-and-butter PC business, and the plan to also cut the mobile chips may be smart.
Atom was an expensive failure
The company poured billions of dollars into its mobile business, but Intel failed to unseat market leader ARM. Atom is available in just a handful of smartphones, and the tablet market is declining. PC makers are replacing tablets with detachable devices and hybrids.
The Atom product line has been in trouble for some time. Atom started off with a bang in netbooks, but its fortunes have sagged since then. Intel’s mobile chip updates haven’t followed a set timeline, and the last Atom chips for servers were released in 2013.
Intel’s mobile strategy is now tied up with 5G, and resources originally dedicated to Sofia and Broxton could be redirected in making 5G chips and modems. The new 5G networks could provide 100 times faster data throughput than 4G, and deployments are expected to start around 2020.
The move to 5G could change the way devices are made. Beyond mobile devices, it will bring speedy mobile connectivity to PCs, smart home devices, robots, drones, wearables, and industrial Internet of Things devices.
The focus on 5G also explains the retention of key mobile executive Aicha Evans by Intel. Earlier this month, it was reported that she was leaving the company after a year of leading the mobile chip business. But she’s a 5G expert and has already outlined the company’s strategy in that area. She will be staying at Intel, though her role is unclear.
The commitment to 5G is a long-term play for Intel, much like its Centrino wireless strategy in 2003 that ultimately made Wi-Fi a ubiquitous feature in laptops. The 5G move also plays into Intel’s preference to focus on future technologies.
Atom’s future could also be in the fast-growing Internet of Things market, which the chip maker is betting on. Variants of the Broxton chip could be used in smart gadgets and sensor devices that collect telemetry, which is then sent to the cloud for analysis.
Intel’s main focus will continue to be on Xeon server chips, cloud computing, field-programmable gate arrays (FPGAs), and silicon photonics.
Revealed: Google AI has access to huge haul of NHS patient data
A data-sharing agreement obtained by New Scientist shows that Google DeepMind’s collaboration with the NHS goes far beyond what it has publicly announced
It’s no secret that Google has broad ambitions in healthcare. But a document obtained by New Scientist reveals that the tech giant’s collaboration with the UK’s National Health Service goes far beyond what has been publicly announced.
The document – a data-sharing agreement between Google-owned artificial intelligence company DeepMind and the Royal Free NHS Trust – gives the clearest picture yet of what the company is doing and what sensitive data it now has access to.
The agreement gives DeepMind access to a wide range of healthcare data on the 1.6 million patients who pass through three London hospitals run by the Royal Free NHS Trust – Barnet, Chase Farm and the Royal Free – each year. This will include information about people who are HIV-positive, for instance, as well as details of drug overdoses and abortions. The agreement also includes access to patient data from the last five years.
“The data-sharing agreement gives Google access to information on millions of NHS patients”
DeepMind announced in February that it was working with the NHS, saying it was building an app called Streams to help hospital staff monitor patients with kidney disease. But the agreement suggests that it has plans for a lot more.
This is the first we’ve heard of DeepMind getting access to historical medical records, says Sam Smith, who runs health data privacy group MedConfidential. “This is not just about kidney function. They’re getting the full data.”
The agreement clearly states that Google cannot use the data in any other part of its business. The data itself will be stored in the UK by a third party contracted by Google, not in DeepMind’s offices. DeepMind is also obliged to delete its copy of the data when the agreement expires at the end of September 2017.
All data needed
Google says that since there is no separate dataset for people with kidney conditions, it needs access to all of the data in order to run Streams effectively. In a statement, the Royal Free NHS Trust says that it “provides DeepMind with NHS patient data in accordance with strict information governance rules and for the purpose of direct clinical care only.”
Still, some are likely to be concerned by the amount of information being made available to Google. It includes logs of day-to-day hospital activity, such as records of the location and status of patients – as well as who visits them and when. The hospitals will also share the results of certain pathology and radiology tests.
As well as receiving this continuous stream of new data, DeepMind has access to the historical data that the Royal Free trust submits to the Secondary User Service (SUS) database – the NHS’s centralised record of all hospital treatments in the UK. This includes data from critical care and accident and emergency departments.
Royal Free did not respond to New Scientist’s questions about what opt-out mechanisms are available to its patients. There is already a way for patients to opt out of SUS data collection, but it is not straightforward and involves writing to your GP. But this does not cover live data on admission, discharge and transfer of patients.
The document also reveals that DeepMind is developing a platform called Patient Rescue, which will provide data analytics services to NHS hospital trusts. It states that Patient Rescue will use data streams from hospitals to build other tools, in addition to Streams, that could carry out real-time analysis of clinical data and support diagnostic decisions. One aim, the agreement says, is for these tools to help medical staff adhere to the UK’s National Institute for Health and Care Excellence guidelines.
DeepMind is not planning to automate clinical decisions – such as what treatments to give patients – but says it wants to support doctors by making predictions based on data that is too broad in scope for an individual to take in.
Comparing a new patient’s information with millions of other cases, Patient Rescue might be able to predict that they are in the early stages of a disease that has not yet become symptomatic, for example. Doctors could then run tests to see if the prediction is correct.
Google declined to discuss what other kinds of tools it could build on the Patient Rescue platform – for instance by setting its artificial intelligences to work on huge volumes of data from millions of patients. However, it has previously stated that early detection of septicaemia – blood poisoning that kills 31,000 people in the UK every year – might be one future application.
The data that DeepMind is collecting will let it make predictions about any disease it wants, says Smith. “What DeepMind is trying to do is build a generic algorithm that can do this for anything – anything you can do a test for.”
We already know the kinds of things that are possible when machine learning is combined with large amounts of high quality medical data. David Clifton, who runs the Computational Health Informatics Lab at the University of Oxford, says his group has already deployed machine learning tools across the four hospitals that are part of the Oxford University Hospitals NHS Foundation Trust. “If you’re in one of these hospitals you’re being monitored with our stuff,” says Clifton.
As well as monitoring the health of individual patients, these systems also watch out for outbreaks of infectious disease. Clifton and his colleagues are also using machine learning on data from Oxford Health NHS Foundation Trust, which provides in-home social care. Clifton says they can use the data to predict things like when a person might develop bipolar disorder.
It is not about replacing doctors or nurses, says Clifton. “It’s about how can we bring the attention of medics to the right place,” he says. “We originally did this in jet engines. There the goal is the same – bringing human expertise to bear on the right part of the system.”
We need not be concerned about Google breaching patient privacy or misusing the data, says Ross Anderson of the University of Cambridge, who taught DeepMind co-founder Demis Hassabis as an undergraduate. In fact, Google has a good track record of keeping data secure and private. “If learning about adverse health outcomes helps them to predict patients at risk, then this is a perfectly reasonable way to make money,” he says.
For Anderson, the more important question is whether Google – already one of the world’s most powerful companies – should have so much control over health analytics. “If Google gets a monopoly on providing some kind of service to the NHS it will burn the NHS,” says Anderson.
Smith has a parallel concern about the knowledge DeepMind is getting via this agreement. “This is private knowledge,” he says. “It’s only going to be available through Google or the Royal Free.”
“Healthcare is going digital in the 21st Century with huge benefits to patients,” says UK life sciences minister George Freeman. “But NHS patients need to know their data will be secure and not be sold or used inappropriately, which is why we have introduced tough new measures to ensure patient confidentiality.”
Google says it has no commercial plans for DeepMind’s work with Royal Free and that the current pilots are being done for free. But the data to which Royal Free is giving DeepMind access is hugely valuable. It may have to destroy its copy of the data when the agreement expires next year, but that gives ample time to mine it for health insights.
Data mining is the name of the game in the burgeoning field of machine learning and artificial intelligence, and there’s no company in the world better at that than Google.
Google’s move into healthcare could make it a target of accusations of anti-competitive activity. It won’t be the first time.
- In 2002, a company called SearchKing sued Google, saying that its dominance in search gave it undue influence over other internet businesses. Google admitted to intentionally destroying SearchKing’s rank in its search engine, but still won the case.
- In 2005, Google was taken to task for making digital copies of 10 million books. Critics complained that Google’s size and influence allowed it to broker a deal with copyright holders that few, if any, other companies could match.
- Since 2010, the European Commission has been investigating allegations of anti-competitive behaviour by Google. The giant is claimed to have abused its dominant position in online search to direct users to its other products, such as maps, flight search and shopping.
This article will appear in print under the headline “Google knows your ills”